At present, the standard first-line and second-line therapies for mCRC are a combination of doublet or cytotoxic triplet chemotherapy and targeted therapies, including anti-epidermal growth factor receptor (EGFR) or anti-vascular endothelial growth factor (VEGF) antibody, the choice of treatment is influenced by patient features, cancer characteristics, and molecular profiles (5–8). Here, VEGFA is linked to cancer.